NCT04178993

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Craig Rush · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.

Conditions

• Methamphetamine Use Disorder

Interventions

Type	Name	Description
DRUG	Methamphetamine	In each arm, subjects will receive doses of methamphetamine.
DRUG	Methylphenidate	In each arm, subjects will receive methylphenidate capsules.
DRUG	Placebo oral capsule	In each arm, subjects will receive placebo capsules.
DRUG	Duloxetine	Subjects will receive duloxetine capsules in the duloxetine arm.

Timeline

• Start date: 2019-09-01
• Primary completion: 2021-05-05
• Completion: 2021-05-05
• First posted: 2019-11-26
• Last updated: 2023-01-09
• Results posted: 2023-01-09

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study